HC Wainwright & Co. Downgrades Galera Therapeutics to Neutral, Lowers Price Target to $0.3
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has downgraded Galera Therapeutics (NASDAQ:GRTX) from Buy to Neutral and lowered the price target from $6 to $0.3.

August 16, 2023 | 10:40 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Galera Therapeutics has been downgraded from Buy to Neutral by HC Wainwright & Co. The price target has also been lowered from $6 to $0.3.
The downgrade from Buy to Neutral indicates a less optimistic outlook for the company's stock. The significant reduction in the price target from $6 to $0.3 suggests that the analyst believes the stock is overvalued at its current price, which could lead to a decrease in the stock price in the short term.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100